Novavax
$103.629876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$103.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$7.27 (+7.63%) Today
+$1.02 (+0.99%) As of 8:00 PM EST after-hours
Why Robinhood?
You can buy or sell Novavax and other stocks, options, and ETFs commission-free!
About NVAX
Novavax, Inc. Common Stock, also called Novavax, is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD. The listed name for NVAX is Novavax, Inc. Common Stock.
CEO
Stanley C. Erck
Employees
165
Headquarters
Gaithersburg, Maryland
Founded
1987
Market Cap
6.53B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
4.03M
High Today
$103.88
Low Today
$94.67
Open Price
$95.32
Volume
3.79M
52 Week High
$189.40
52 Week Low
$3.65
Collections
Digestible Financial News
Jack Kramer & Nick Martell
Managing Editors of News & Snacks at Robinhood Financial LLC
NVAX News
NVAX Earnings
-$3.21
-$1.56
$0.08
$1.73
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours